Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Chosa

MCap

SEK57m

Last close

SEK0.80

▲ 0.20 (33.33%)

Vection Technologies

MCap

AUD47m

Last close

AUD0.04

▲ 0.00 (12.90%)

Metro Bank

MCap

GBP684m

Last close

GBP1.02

▲ 7.90 (8.43%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Actinogen Medical – executive interview

Actinogen Medical – executive interview

Actinogen Medical — 5 videos in collection

More on this equity

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11β-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

In this interview, chief executive officer Dr Steven Gourlay describes the commercial opportunities and next development steps for Xanamem in Alzheimer’s disease (AD) and for CI in relation to major depressive disorder. He also discusses promising indications of therapeutic activity from a recent analysis of patients in its XanADu study in mild AD with confirmed disease through blood biomarker testing.

< Previous

Next >

You may also be interested in these:

Healthcare

27.09.23

Actinogen Medical – executive interview

Healthcare

08.02.22

Actinogen: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free